Intratumor Electrotransfer of RNA Therapeutics (IERT)

RNAi is a powerful technology to identify new targets. Typically, lentiviral-shRNA vectors are generated for in vitro studies. At Takis we use in vivo electroporation to assess the effects of target knock-down and explore the efficacy of new combination treatments in vivo.

  • Intratumoral delivery. Can be used also for normal tissues.
  • Allows rapid screening and prioritization of targets and related RNA therapeutics
  • Easy access to tumor biopsies for direct evaluation of target knock down


Intratumor electrotransfer

Follow Us on Linkedin

Takis is a biotech dedicated to cancer research. Our primary objective is the development of innovative therapies based on the principle that our immune system can be “instructed” to recognize the tumor and reject it as a foreign entity.